4dMT Revenue Jumps 200 Percent in Q2

4d Molecular Therapeutics (NASDAQ:FDMT), a clinical-stage genetic medicines company specializing in targeted gene therapies, reported financial results for the second quarter of fiscal 2025 on August 11, 2025. The headline news was a dramatic revenue surge, with the company delivering $15.0 million (GAAP) revenue. The quarter also saw a larger-than-expected loss per share of -$0.98 (GAAP), versus the forecasted loss of -$0.73. Overall, the period showed meaningful advancement of core clinical programs alongside a higher rate of research spending and an increased net loss, offset in part by clear clinical and operational milestones for its lead therapies. Source: Analyst estimates for the quarter provided by FactSet. 4d Molecular Therapeutics develops genetic medicines using its proprietary Therapeutic Vector Evolution (TVE) platform, which enables the creation of custom-built adeno-associated virus (AAV) vectors designed to deliver genes precisely to targeted tissues. The company focuses its product development on two core programs: 4D-150, a gene therapy for retinal diseases such as wet age-related macular degeneration (AMD) and diabetic macular edema (DME); and 4D-710, a gene therapy in respiratory disease, specifically cystic fibrosis. The company's progress depends on advancing these candidates through clinical trials, securing regulatory designations, and validating the TVE platform's capabilities for more effective and durable gene delivery.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool